NASDAQ:ZFGN - Zafgen Stock Price, Price Target & More

$6.76 -0.08 (-1.17 %)
(As of 04/23/2018 11:18 AM ET)
Previous Close$6.84
Today's Range$6.51 - $6.92
52-Week Range$3.21 - $10.00
Volume46,458 shs
Average Volume201,738 shs
Market Capitalization$188.50 million
P/E Ratio-3.47
Dividend YieldN/A
Beta-0.56

About Zafgen (NASDAQ:ZFGN)

Zafgen logoZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

Receive ZFGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZFGN
CUSIPN/A
Phone617-622-4003

Debt

Debt-to-Equity Ratio0.26%
Current Ratio14.39%
Quick Ratio14.39%

Price-To-Earnings

Trailing P/E Ratio-3.47
Forward P/E Ratio-3.07
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.85 per share
Price / Book2.37

Profitability

EPS (Most Recent Fiscal Year)($1.90)
Net Income$-52,020,000.00
Net MarginsN/A
Return on Equity-55.08%
Return on Assets-48.40%

Miscellaneous

Employees35
Outstanding Shares27,560,000

How to Become a New Pot Stock Millionaire

Zafgen (NASDAQ:ZFGN) Frequently Asked Questions

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

How were Zafgen's earnings last quarter?

Zafgen (NASDAQ:ZFGN) posted its quarterly earnings data on Tuesday, March, 6th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.57) by $0.09. View Zafgen's Earnings History.

When is Zafgen's next earnings date?

Zafgen is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Zafgen.

What price target have analysts set for ZFGN?

1 analysts have issued 12-month price objectives for Zafgen's shares. Their forecasts range from $20.00 to $20.00. On average, they expect Zafgen's stock price to reach $20.00 in the next year. View Analyst Ratings for Zafgen.

Who are some of Zafgen's key competitors?

Who are Zafgen's key executives?

Zafgen's management team includes the folowing people:
  • Dr. Thomas E. Hughes, Pres, Chief Scientific Officer & Director (Age 58)
  • Ms. Patricia L. Allen CPA, Chief Financial Officer (Age 56)
  • Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 48)
  • Mr. Jeffrey S. Hatfield, CEO & Director (Age 60)
  • Dr. James E. Vath Ph.D., Head of Discovery and Devel. (Age 57)

Has Zafgen been receiving favorable news coverage?

News articles about ZFGN stock have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zafgen earned a daily sentiment score of 0.03 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.70 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Zafgen?

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zafgen's stock price today?

One share of ZFGN stock can currently be purchased for approximately $6.59.

How big of a company is Zafgen?

Zafgen has a market capitalization of $188.50 million. The biopharmaceutical company earns $-52,020,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 35 workers across the globe.

How can I contact Zafgen?

Zafgen's mailing address is 175 PORTLAND STREET 4TH FLOOR, BOSTON MA, 02114. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]


MarketBeat Community Rating for Zafgen (ZFGN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  377
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zafgen (NASDAQ:ZFGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Zafgen in the last 12 months. Their average twelve-month price target is $20.00, suggesting that the stock has a possible upside of 195.86%. The high price target for ZFGN is $20.00 and the low price target for ZFGN is $20.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.502.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.00$14.50$9.00$9.00
Price Target Upside: 195.86% upside75.54% upside83.67% upside83.67% upside

Zafgen (NASDAQ:ZFGN) Consensus Price Target History

Price Target History for Zafgen (NASDAQ:ZFGN)

Zafgen (NASDAQ:ZFGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2018JMP SecuritiesReiterated RatingOutperform$11.00 -> $20.00HighView Rating Details
4/20/2017Roth CapitalInitiated CoverageBuy -> Buy$9.00HighView Rating Details
3/10/2017CowenReiterated RatingHoldN/AView Rating Details
3/7/2017FBR & CoReiterated RatingMarketperformLowView Rating Details
7/21/2016Canaccord GenuitySet Price TargetHold$7.00 -> $4.00N/AView Rating Details
7/20/2016Leerink SwannReiterated RatingMarket Perform$6.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Zafgen (NASDAQ:ZFGN) Earnings History and Estimates Chart

Earnings by Quarter for Zafgen (NASDAQ:ZFGN)

Zafgen (NASDAQ:ZFGN) Earnings Estimates

2018 EPS Consensus Estimate: ($2.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.53)($0.53)($0.53)
Q2 20181($0.54)($0.54)($0.54)
Q3 20181($0.58)($0.58)($0.58)
Q4 20181($0.54)($0.54)($0.54)

Zafgen (NASDAQ ZFGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.52)N/AView Earnings Details
3/6/2018Q4 2017($0.57)($0.48)ViewListenView Earnings Details
11/7/2017Q3 2017($0.58)($0.46)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.52)($0.49)ViewListenView Earnings Details
5/9/2017Q1 2017($0.4260)($0.48)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.50)($0.38)ViewListenView Earnings Details
11/9/2016Q3 2016($0.65)($0.54)ViewN/AView Earnings Details
8/4/2016Q2 2016($0.67)($0.55)ViewN/AView Earnings Details
5/10/2016Q116($0.74)($0.65)ViewListenView Earnings Details
3/9/2016Q415($0.80)($0.85)ViewN/AView Earnings Details
11/10/2015Q3($0.79)($0.73)$80.60 million$78.20 millionViewListenView Earnings Details
8/11/2015Q215($0.71)($0.66)ViewListenView Earnings Details
5/12/2015Q115($0.52)($0.53)ViewListenView Earnings Details
3/19/2015Q414($0.84)($0.48)ViewListenView Earnings Details
11/11/2014Q314($0.87)($0.65)ViewN/AView Earnings Details
8/13/2014Q214($0.28)($2.96)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Zafgen (NASDAQ:ZFGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Zafgen (NASDAQ ZFGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.20%
Institutional Ownership Percentage: 52.18%
Insider Trading History for Zafgen (NASDAQ:ZFGN)
Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)

Zafgen (NASDAQ ZFGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/7/2018Thomas E. HughesInsiderSell5,000$10.00$50,000.00View SEC Filing  
10/13/2017Frances K HellerDirectorBuy10,000$3.90$39,000.00View SEC Filing  
7/11/2017Dennis D KimInsiderBuy10,000$3.39$33,900.0021,443View SEC Filing  
5/11/2017Dennis D. KimInsiderBuy10,000$4.40$44,000.00View SEC Filing  
12/19/2016Frances K HellerDirectorBuy10,000$3.23$32,300.0030,000View SEC Filing  
11/15/2016Frances K HellerDirectorBuy10,000$3.54$35,400.0020,000View SEC Filing  
8/29/2016Thomas E HughesInsiderBuy10,000$3.00$30,000.0063,936View SEC Filing  
7/26/2016Patricia L. AllenCFOBuy16,000$3.12$49,920.00View SEC Filing  
7/22/2016Frances K HellerDirectorBuy10,000$2.99$29,900.0010,000View SEC Filing  
7/22/2016Thomas E. HughesInsiderBuy5,000$3.02$15,100.00View SEC Filing  
2/12/2016James E FlynnInsiderBuy64,545$6.25$403,406.25View SEC Filing  
2/11/2016James E FlynnInsiderBuy267,493$6.02$1,610,307.86View SEC Filing  
9/24/2015Kevin P StarrDirectorSell136,579$43.90$5,995,818.10370,323View SEC Filing  
9/18/2015Avi Y GoldbergDirectorSell5,000$45.00$225,000.0053,734View SEC Filing  
9/18/2015Thomas E. HughesCEOSell45,626$42.53$1,940,473.78820View SEC Filing  
9/17/2015Dennis D. KiminsiderSell39,407$40.00$1,576,280.00View SEC Filing  
6/10/2015Avi Y GoldbergDirectorSell3,000$35.00$105,000.00View SEC Filing  
6/1/2015Avi Y GoldbergDirectorSell2,000$32.23$64,460.00View SEC Filing  
6/19/2014Alicia SecorInsiderBuy4,000$20.00$80,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Zafgen (NASDAQ ZFGN) News Headlines

Source:
DateHeadline
ValuEngine Downgrades Zafgen (ZFGN) to Strong SellValuEngine Downgrades Zafgen (ZFGN) to Strong Sell
www.americanbankingnews.com - April 21 at 7:06 AM
Zafgen (ZFGN) Rating Increased to Sell at ValuEngineZafgen (ZFGN) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - April 12 at 10:47 AM
 Analysts Expect Zafgen (ZFGN) to Announce -$0.53 EPS Analysts Expect Zafgen (ZFGN) to Announce -$0.53 EPS
www.americanbankingnews.com - April 10 at 5:22 AM
ValuEngine Lowers Zafgen (ZFGN) to Strong SellValuEngine Lowers Zafgen (ZFGN) to Strong Sell
www.americanbankingnews.com - April 7 at 8:19 PM
 Analysts Anticipate Zafgen Inc (ZFGN) to Post -$0.53 EPS Analysts Anticipate Zafgen Inc (ZFGN) to Post -$0.53 EPS
www.americanbankingnews.com - March 24 at 5:24 AM
Zafgen (ZFGN) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowZafgen (ZFGN) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 5:39 PM
Zafgen (ZFGN) Downgraded by Zacks Investment Research to HoldZafgen (ZFGN) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 9 at 9:02 PM
Insider Selling: Zafgen Inc (ZFGN) Insider Sells 5,000 Shares of StockInsider Selling: Zafgen Inc (ZFGN) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - March 9 at 7:15 PM
Zafgen Inc to Post Q2 2018 Earnings of ($0.54) Per Share, Leerink Swann Forecasts (ZFGN)Zafgen Inc to Post Q2 2018 Earnings of ($0.54) Per Share, Leerink Swann Forecasts (ZFGN)
www.americanbankingnews.com - March 9 at 8:04 AM
Here's Why Zafgen Inc Rose as Much as 21.1% TodayHere's Why Zafgen Inc Rose as Much as 21.1% Today
finance.yahoo.com - March 7 at 5:58 PM
Zafgen to Present at Cowen 38th Annual Health Care ConferenceZafgen to Present at Cowen 38th Annual Health Care Conference
finance.yahoo.com - March 7 at 5:58 PM
Zafgen (ZFGN) Raised to Buy at Zacks Investment ResearchZafgen (ZFGN) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 7 at 3:08 PM
Zafgen (ZFGN) Rating Reiterated by JMP SecuritiesZafgen (ZFGN) Rating Reiterated by JMP Securities
www.americanbankingnews.com - March 7 at 1:17 PM
Zafgen (ZFGN) Issues  Earnings ResultsZafgen (ZFGN) Issues Earnings Results
www.americanbankingnews.com - March 7 at 7:54 AM
Zafgen Inc (ZFGN) Expected to Announce Earnings of -$0.59 Per ShareZafgen Inc (ZFGN) Expected to Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - March 7 at 1:16 AM
BRIEF-Zafgen Reports Q4 Loss Per Share $0.48BRIEF-Zafgen Reports Q4 Loss Per Share $0.48
www.reuters.com - March 6 at 5:20 PM
Zafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 DiabetesZafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
finance.yahoo.com - March 6 at 5:20 PM
Royce & Associates LP Grows Position in Zafgen Inc (ZFGN)Royce & Associates LP Grows Position in Zafgen Inc (ZFGN)
www.americanbankingnews.com - March 6 at 10:52 AM
AWM Investment Company Inc. Acquires Shares of 400,264 Zafgen Inc (ZFGN)AWM Investment Company Inc. Acquires Shares of 400,264 Zafgen Inc (ZFGN)
www.americanbankingnews.com - March 6 at 4:46 AM
Leerink Swann Weighs in on Zafgen Incs FY2019 Earnings (ZFGN)Leerink Swann Weighs in on Zafgen Inc's FY2019 Earnings (ZFGN)
www.americanbankingnews.com - March 5 at 7:56 AM
Acer Therapeutics (ACER) & Zafgen (ZFGN) Critical ContrastAcer Therapeutics (ACER) & Zafgen (ZFGN) Critical Contrast
www.americanbankingnews.com - March 4 at 9:15 PM
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 3 at 8:42 AM
Equities Analysts Set Expectations for Zafgen Incs Q1 2018 Earnings (ZFGN)Equities Analysts Set Expectations for Zafgen Inc's Q1 2018 Earnings (ZFGN)
www.americanbankingnews.com - March 2 at 8:06 AM
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial ResultsZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 5:28 PM
Zafgen (ZFGN) Set to Announce Earnings on WednesdayZafgen (ZFGN) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:58 AM
 Brokerages Anticipate Zafgen Inc (ZFGN) to Announce -$0.59 Earnings Per Share Brokerages Anticipate Zafgen Inc (ZFGN) to Announce -$0.59 Earnings Per Share
www.americanbankingnews.com - February 18 at 12:08 PM
Zafgen (ZFGN) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowZafgen (ZFGN) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 15 at 5:02 PM
Zafgen to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceZafgen to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 9:38 AM
Zafgen (ZFGN) Raised to Sell at ValuEngineZafgen (ZFGN) Raised to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 6:52 AM
Zymeworks (ZYME) and Zafgen (ZFGN) Financial ContrastZymeworks (ZYME) and Zafgen (ZFGN) Financial Contrast
www.americanbankingnews.com - January 17 at 9:14 PM
Zafgen (ZFGN) Downgraded to "Hold" at Zacks Investment ResearchZafgen (ZFGN) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 13 at 4:08 PM
Blog Exposure - Zafgen Reports Strong Clinical Progress and Updates OutlookBlog Exposure - Zafgen Reports Strong Clinical Progress and Updates Outlook
finance.yahoo.com - January 8 at 10:43 AM
Zafgen (ZFGN) Announces Strong Clinical Progress and Updates Outlook for 2018Zafgen (ZFGN) Announces Strong Clinical Progress and Updates Outlook for 2018
www.streetinsider.com - January 6 at 10:32 AM
BRIEF-Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount Of $20 MlnBRIEF-Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount Of $20 Mln
www.reuters.com - January 6 at 10:32 AM
Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018  Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018  
finance.yahoo.com - January 5 at 10:48 AM
-$0.59 Earnings Per Share Expected for Zafgen Inc (ZFGN) This Quarter-$0.59 Earnings Per Share Expected for Zafgen Inc (ZFGN) This Quarter
www.americanbankingnews.com - December 29 at 3:22 PM
Zafgen, Inc. (ZFGN) Receives Average Rating of "Hold" from AnalystsZafgen, Inc. (ZFGN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - December 15 at 3:54 PM
-$0.59 EPS Expected for Zafgen, Inc. (ZFGN) This Quarter-$0.59 EPS Expected for Zafgen, Inc. (ZFGN) This Quarter
www.americanbankingnews.com - December 12 at 11:36 AM
Zafgen, Inc. (ZFGN) Expected to Announce Earnings of -$0.59 Per ShareZafgen, Inc. (ZFGN) Expected to Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - November 24 at 1:18 PM
Zafgen, Inc. (ZFGN) Receives Average Recommendation of "Hold" from AnalystsZafgen, Inc. (ZFGN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 20 at 3:46 PM
Zacks Investment Research Upgrades Zafgen, Inc. (ZFGN) to "Buy"Zacks Investment Research Upgrades Zafgen, Inc. (ZFGN) to "Buy"
www.americanbankingnews.com - November 11 at 10:22 AM
Leerink Swann Comments on Zafgen, Inc.s FY2017 Earnings (ZFGN)Leerink Swann Comments on Zafgen, Inc.'s FY2017 Earnings (ZFGN)
www.americanbankingnews.com - November 10 at 12:26 PM
Zafgen, Inc. (ZFGN) Announces Quarterly  Earnings Results, Beats Expectations By $0.12 EPSZafgen, Inc. (ZFGN) Announces Quarterly Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - November 8 at 7:11 PM
Zafgen Reports Third Quarter 2017 Financial ResultsZafgen Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 9:28 PM
Zafgen reports 3Q lossZafgen reports 3Q loss
finance.yahoo.com - November 7 at 9:28 PM
Head to Head Contrast: Zafgen (ZFGN) & Its RivalsHead to Head Contrast: Zafgen (ZFGN) & Its Rivals
www.americanbankingnews.com - November 1 at 3:12 AM
Zafgen, Inc. (ZFGN) Set to Announce Quarterly Earnings on TuesdayZafgen, Inc. (ZFGN) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:52 AM
Financial Contrast: Zafgen (ZFGN) versus Its CompetitorsFinancial Contrast: Zafgen (ZFGN) versus Its Competitors
www.americanbankingnews.com - October 30 at 11:40 AM
Zafgen Inc (ZFGN) Receives Average Rating of "Hold" from BrokeragesZafgen Inc (ZFGN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 26 at 5:48 PM
Zafgen, Inc. (ZFGN) Director Acquires $39,000.00 in StockZafgen, Inc. (ZFGN) Director Acquires $39,000.00 in Stock
www.americanbankingnews.com - October 17 at 8:18 PM

SEC Filings

Zafgen (NASDAQ:ZFGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zafgen (NASDAQ:ZFGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zafgen (NASDAQ ZFGN) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.